MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.350
-0.040 (-2.88%)
At close: Aug 24, 2026, 4:00 PM EDT
1.400
+0.050 (3.70%)
Pre-market: Aug 25, 2026, 4:07 AM EDT
MAIA Biotechnology Employees
MAIA Biotechnology had 13 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,065,015
Market Cap
82.11M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 13 | 0 | - |
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | -5 | -27.78% |
| Dec 31, 2022 | 18 | 9 | 100.00% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Verrica Pharmaceuticals | 76 |
| Elicio Therapeutics | 33 |
| Cardiff Oncology | 31 |
| Gain Therapeutics | 21 |
| Cingulate | 14 |
| Eloxx Pharmaceuticals | 10 |
| Alterity Therapeutics | 9 |
MAIA News
- 3 days ago - MAIA Biotechnology files $150M mixed securities shelf - TheFly
- 3 days ago - MAIA Biotechnology Registration statement: Registration filing - Filings
- 7 days ago - Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - GlobeNewsWire
- 14 days ago - MAIA Biotechnology Quarterly report: Q2 2026 - Filings
- 6 weeks ago - MAIA Biotechnology reports efficacy data from Phase 2 THIO-101 Part C expansion - TheFly
- 6 weeks ago - MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial - GlobeNewsWire
- 2 months ago - MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer - GlobeNewsWire
- 2 months ago - MAIA Biotechnology opens third clinical site in U.S. for Phase 2 THIO-101 trial - TheFly